News | Astellas Pharma Inc.
WEBAstellas Receives Approval from the European Commission for VYLOY TM (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
News | Astellas Pharma Inc.
WEB1 day ago · News from Astellas. Latest and past news available. TOKYO, October 10, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZATM (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, …
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World …
WEB1 day ago · TOKYO, Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for ...
News | Astellas Pharma Inc.
WEB3 days ago · Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality.
FDA Grants iota Biosciences IDE Approval for First-In-Human Early ...
WEB22 hours ago · ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today ...
Astellas and AviadoBio Announce Exclusive Option and License …
WEB3 days ago · News provided by. Astellas Pharma Inc. Oct 08, 2024, 09:27 ET. Share this article. Share to X. Share this article. Share to X. Astellas receives an exclusive option to license AVB-101, an ...
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier …
WEBNov 16, 2023 · With this approval, XTANDI becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).
Astellas places $2bn+ bet on AviadoBio dementia gene therapy
WEB3 days ago · Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million. The ...
Astellas to Present VEOZA™ (fezolinetant) Data at IMS ... - BioSpace
WEB1 day ago · Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality.
Astellas and Kelonia Therapeutics Enter into Research and License ...
WEBTOKYO and BOSTON, Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D.,...
- Some results have been removed